Following a 40% decline, now looks good for scaling into the stock.
Despite positives we see, the investor community seems unconvinced of CGEN's potential.
This cardiac monitoring device company has bullish technicals and volume that show potential for 30% upside.
The stock still maintains a bullish slant on the daily chart.
Regeneron shows its relative strength in the market selloff.
With a pending merger pushing the stock, the technical picture still looks strong.
At first glance there is little connection, but you need to look deeper.
Valeant Pharmaceuticals' technicals look bullish with a strong base and support.
Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.

Columnist Conversations

I have shorted today's ramp into tomorrow's #. See next post.
So far, the current upmove in the Emini S&P 500 has peaked at 1973.50, which is in the vicinity of the pri...
out of these for now as we saw no followthrough on tues. SOLD SPY 195 PUT AT 2.70 (IN AT 5.40) SOLD DIA SEPT 1...
Kohl's is moving nicely higher today. Shares are up over 2% and appear to be leaving behind a solid shor...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.